Heartwatch: a secondary prevention programme in primary care in Ireland

Abstract

Background

Heartwatch, a secondary prevention programme in primary care was initiated in 2003, based on the second European Joint Task Force recommendations for secondary prevention of coronary heart disease (CHD). The aim was to examine the effect of the first 2 years of the Heartwatch programme on cardiovascular risk factors and treatments.

Design

Prospective cohort study of patients with established CHD enrolled into the Heartwatch programme.

Methods

Four hundred and seventy (20%) general practitioners nationwide participated in the programme, recruiting 11542 patients with established CHD (earlier myocardial infarction, coronary intervention or coronary artery bypass surgery). Clinical data were electronically transferred by each general practitioner to a central database. Comparison of changes in risk factors and treatments at 1-year and 2-year follow-up from baseline were made using paired t-test for continuous and McNemar's test for categorical data.

Results

Statistically significant changes in systolic blood pressure, diastolic blood pressure, total and low-density lipoprotien cholesterol and smoking status at 1 and 2 years (P < 0.0001) were observed. Little or no improvements were shown for exercise, BMI or waist circumference. Increases in the prescribing of statins, angiotensin-converting enzyme inhibitors and β-blockers over the course of the study were observed.

Conclusion

The Heartwatch programme has demonstrated significant improvements in the main risk factors and treatments for CHD. More effective interventions are required to reduce BMI, waist circumference and physical inactivity in this population. The increases in treatment uptake are approaching the optimal levels in this population. Eur J Cardiovasc Prev Rehabil 15:651–656 © 2008 The European Society of Cardiology

Keywords

coronary heart disease Ireland primary care risk factors secondary prevention treatments

Get full access to this article

View all access options for this article.

References

Allender

Scarborough

Peto

Rayner

. European cardiovascular disease statistics. Brussels: European Heart Network; 2008.

Antithrombotic trialists' collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324:71–86.

Freemantle

Cleland

Young

Mason

Harrison

. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999; 318:1730–1737.

Garg

Yusuf

. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. J Am Med Assoc 1995; 273:1450–1465.

Wilt

Bloomfield

MacDonald

Nelson

Rutks

Effectiveness of statin therapy in adults with coronary heart disease. Ann Intern Med 2005; 164:1427–1436.

Yusuf

Peto

Lewis

Collins

Sleight

. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 318:1730–1737.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7–22.

Yusuf

Hawken

Ounpuu

Dans

Avezum

Lanas

On behalf of the INTERHEART study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937–952.

Taylor

Brown

Ebrahim

Jolliffe

Noorani

Rees

Exercise-based rehabination for patients with coronary heart disease: systematic review and metaanalysis of randomized controlled trials. Am J Med 2004; 116:682–692.

10.

Building Healthier Hearts. Report of the Cardiovascular Health Strategy Group, Stationery Office, Dublin, 1999.

11.

Wood

De Backer

Faergeman

Graham

Mancia

Pyörälä

Second Joint Task Force of European and other Societies on Coronary Prevention. Prev Coron Dis Clin Pract Atherosclerolosis 1998; 140:199–270.

12.

De Backer

Ambrosiono

Borch-Johnsen

Brotons

Cifkova

Dallongeville

Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice

Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl 1):S1–S78.

13.

Bennett

Kabir

Unal

Shelley

Critchley

Perry

Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985–2000. J Epidemiol Community Health 2006; 60:322–327.

14.

Law

Wald

Rudnicka

. Quantifying effect of statins on low density lipoprotein cholesterol, Ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003; 326:1423–1429.

15.

Graham

Atar

Borch-Johnsen

Boysen

Burell

Cifkova

European guidelines on cardiovascular disease prevention in clinical practice: full text: Fourth Joint Task Force of The European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)

Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2):S1–S113.

16.

EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principle results from EUROASPIRE II Heart Survey Programme. Eur Heart J 2001; 22:554–572.

17.

EUROACTION Study. www.escardio.org/EUROACTION.

18.

Stagmo

Israelsson

Brandstrom

Hedback

Lingfors

Nilsson

The Swedish National Programme for Quality Control of Secondary Prevention of Coronary Artery Disease – results after one year. Eur J Cardiovasc Prev Rehabil 2004; 11:18–24.

19.

Campbell

Ritchie

Thain

Deans

Rawles

Squair

. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart 1998; 80:447–452.

20.

Moher

Yudkin

Wright

Turner

Fuller

Scholfield

Cluster randomised controlled trial to compared three methods of promoting secondary prevention of coronary heart disease in primary care. Br Med J 2001; 322:1338–1345.

21.

Errikson

Westborg

Eliasson

. A randomised trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors. Scand J Public Health 2006; 34:453–461.

22.

De Velasco

Rodriguez

Ridocci

Aznar

. Action to improve secondary prevention in coronary heart disease patients: one year follow-up of a shared care programme E Heart J Suppl 2004; 6 (Suppl J):J27–J232.

23.

Mant

Mcmanus

Hare

. Applicability to primary care of national clinical guidelines on blood pressure lowering for people with stroke: cross sectional study. Br Med J 2006; 332:635–637.

24.

Heartwatch Clinical Report. Stationery Office. Dublin, 2006.